Donate
|
Join/Renew
|
Store
|
Member Directory
|
My SNMMI
Search SNMMI.org
Search SNMMI Learning Center
Value Initiative
|
Physicians
|
Technologists
|
Scientists
|
Residents
|
Healthcare Provider
|
Patients
NEWS & PUBLICATIONS
News and Media
Newsletters
Journals
Books
MEMBERSHIP
Join/Renew
Benefits
Categories
Download a Member Application
Grants, Awards, and Scholarships
Access the Phantom Analysis Toolkit
Membership Directory
Chapters
Centers of Excellence
Councils
Member Spotlight
Women in Nuclear Medicine
SNMMI Fellow
SNMMI-TS Fellow
Council and Center Internships
EDUCATION
Learning Center
Webinars
MEETINGS & EVENTS
Calendar of Events
Webinars
2024 Annual Meeting
2024 Therapeutics Conference
2024 Mid-Winter Meeting
Nuclear Medicine & Molecular Imaging Week
ADVOCACY
Coding & Reimbursement
Legislative Efforts
Government Relations News
Radiopharmaceutical Supply News
USP 825
Technologist State Issues
Position Statements
FDA PET Drug Manufacturing Q&A
EVIDENCE & QUALITY
Clinical Guidelines and AUC
Quality
Quality and Patient Safety
Dose Optimization
About Quality & Practice
Dosimetry
RESEARCH
Clinical Trials Network
Radiopharmaceutical Therapy Central
Radiopharmaceutical Therapy Centers of Excellence
Preclinical Imaging
Nuclear Medicine Clinical Trial Group, LLC
Research: Learn More
ABOUT SNMMI
Strategic Plan
Bylaws & Procedures
Governance - SNMMI
Governance - SNMMI-TS
History
Grants, Awards, and Scholarships
Career Center
About Nuclear Medicine & Molecular Imaging
International Collaboration
Outreach
Support SNMMI
Contact Us
HOME
>
ADVOCACY
>
FDA PET Drug Manufacturing Q&A
In This Section
Coding & Reimbursement
For Hospitals (APCs, IPPS)
For Private Practices (RBRVS)
Coding Q&As
Coding News
Legislative Efforts
Government Relations News
Radiopharmaceutical Supply News
USP 825
Technologist State Issues
State TAG Team
How to be a Grassroots Advocate
Position Statements
FDA PET Drug Manufacturing Q&A
Advertisement
FDA Inspections Q&A
Please
Login
as a SNMMI Member to access the FDA Inspections Q&As.
